Study identifier:D4022L00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A five-arm, randomised, open label, multi-centre, prospective study to compare the efficacy, safety and tolerability of Metoprolol XL plus Amlodipine combination (Selomax TM) with Metoprolol XL and Amlodipine as individual components in management of hypertension in Indian patients.
Primary hypertension
Phase 4
No
Metoprolol XL 50mg + Amlodipine 5mg, Metoprolol XL 25 mg + Amlodipine 2.5mg, Metoprolol XL 50mg, Metoprolol XL 25 mg, Amlodipine 5mg
All
402
Interventional
18 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Sept 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
St.John's Clinical Research Institute, Bangalore, India
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 FDC of Metoprolol XL 50mg + Amlodipine 5mg | Drug: Metoprolol XL 50mg + Amlodipine 5mg tablet,oral,OD,8 weeks Other Name: Selomax 50/5 |
Experimental: 2 FDC of Metoprolol XL 25mg + Amlodipine 2.5mg | Drug: Metoprolol XL 25 mg + Amlodipine 2.5mg tablet,oral,OD,8 weeks Other Name: Selomax 25/2.5 |
Active Comparator: 3 Extended release Metoprolol succinate | Drug: Metoprolol XL 50mg tablet,oral,OD,8 weeks Other Name: Revelol XL |
Active Comparator: 4 Extended release Metoprolol succinate | Drug: Metoprolol XL 25 mg tablet,oral,OD,8 weeks Other Name: Revelol XL |
Active Comparator: 5 Amlodipine 5mg in immediate release formulation | Drug: Amlodipine 5mg tablet,oral,OD,8 weeks Other Name: Amlogard |